No new signals for lecanemab emerged in ALZ-NET ...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other ...

Early real-world safety data from the ALZ-NET registry show lecanemab’s side effect profile aligns with clinical trial findings, with no new safety concerns. The registry, launched in 2022, tracks ...

STRONG WILL BE PARTICIPATING IN THE RIDE TO END ALZHEIMER’S IN SOUTH CAROLINA CYCLING MORE THAN 200 MILES TO RAISE MONEY AND AWARENESS FOR ALZHEIMER’S. IN MAY OF 2021. WYFF NEWS FORCE GEOFF HART ...

In April, the future was looking bleak for an experimental Alzheimer's drug called valiltramiprosate, or ALZ-801. Researchers had just released topline results of a study of more than 300 people age ...

Please provide your email address to receive an email when new articles are posted on . Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a ...

Friday, April 17, is “End Alz Day”, a day of unity in the fight against Alzheimer’s. “On this day, we stand together to raise ...

NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced ...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and diagnostic assays for patients with ...

NEWBERRY, S.C. (WCSC) - The July heat isn’t stopping hundreds of cyclists from pedaling from one side of South Carolina to the other over the next three days. Their goal is to support those fighting ...

MOUNT PLEASANT, S.C. (WCIV) — Over 400 cyclists completed a 3-day, 257-mile ride across South Carolina in support of the Alzheimer's Association Sunday as the 2025 Ride to End ALZ wrapped up in Mount ...